Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
Puma Biotechnology, Inc. (PBYI) will host a conference call to discuss its fourth quarter and full year 2023 financial results on February 29, 2024. The call will provide insights into the company's performance and future outlook.
02/15/2024 - 04:10 PM
LOS ANGELES --(BUSINESS WIRE)--
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 29, 2024, following the release of its fourth quarter and full year 2023 financial results.
The call may be accessed by dialing (877) 709-8150 (domestic) or (201) 689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com . A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215062395/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
David Schull or Olipriya Das, Russo Partners, +1 212 845 4200
david.schull@russopartnersllc.com
olipriya.das@russopartnersllc.com
Source: Puma Biotechnology, Inc.
When will Puma Biotechnology host a conference call to discuss its financial results?
Puma Biotechnology will host a conference call on February 29, 2024, at 1:30 p.m. PST/4:30 p.m. EST.
How can I access the conference call?
The conference call can be accessed by dialing (877) 709-8150 (domestic) or (201) 689-8354 (international) at least 10 minutes in advance.
Where can I find the presentation slides for the conference call?
Presentation slides for the conference call can be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com.
Will there be a replay of the conference call available?
Yes, a replay of the conference call will be available approximately one hour after completion of the call and will be archived on Puma's website for 90 days.
